AI Article Synopsis
- Interleukin-17 (IL-17) has gained attention for its significant role in causing proinflammatory immune responses, making it a key target for drug development.
- Researchers are developing monoclonal antibodies to inhibit IL-17, which shows promise in treating inflammatory diseases.
- This review focuses on the results from clinical trials of IL-17 inhibitors specifically for conditions like psoriasis and psoriatic arthritis, mentioning drugs like secukinumab, ixekizumab, bimekizumab, and brodalumab.
Article Abstract
In recent years, the role of interleukin-17 (IL-17) in orchestrating and manipulating proinflammatory immune responses has received special attention. It has become apparent from murine studies and clinical trials that due to its inhibitory effect on immunoregulation and its stimulatory action on promoting proinflammatory responses, IL-17 is an ideal cytokine to target for drug development, in order to cease its induction or eliminate IL-17-producing cells of any kind. Several monoclonal antibodies have been developed and tested as potent inhibitors of IL-17 in various inflammatory diseases. This review summarizes data from relevant clinical trials on recent developments of the application of inhibitors of IL-17 in psoriasis and psoriatic arthritis, namely secukinumab, ixekizumab, bimekizumab and brodalumab.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1358/dot.2023.59.3.3419557 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!